YHB Investment Advisors Inc. decreased its holdings in shares of Danaher Corporation (NYSE:DHR) by 8.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 93,798 shares of the conglomerate’s stock after selling 8,164 shares during the quarter. Danaher Corporation comprises about 1.4% of YHB Investment Advisors Inc.’s investment portfolio, making the stock its 20th biggest position. YHB Investment Advisors Inc.’s holdings in Danaher Corporation were worth $8,046,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of DHR. Bridgewater Associates LP acquired a new stake in shares of Danaher Corporation during the first quarter worth $1,423,000. Front Street Capital Management Inc. acquired a new stake in shares of Danaher Corporation during the first quarter worth $2,391,000. Stephens Inc. AR boosted its holdings in shares of Danaher Corporation by 0.3% during the first quarter. Stephens Inc. AR now owns 77,545 shares of the conglomerate’s stock worth $6,632,000 after purchasing an additional 212 shares during the last quarter. Bellevue Group AG boosted its holdings in shares of Danaher Corporation by 54.1% during the first quarter. Bellevue Group AG now owns 114,000 shares of the conglomerate’s stock worth $9,750,000 after purchasing an additional 40,000 shares during the last quarter. Finally, Israel Discount Bank of New York purchased a new position in shares of Danaher Corporation in the 1st quarter worth $209,000. Institutional investors and hedge funds own 75.56% of the company’s stock.

Danaher Corporation (NYSE DHR) traded up $0.05 during trading hours on Friday, reaching $93.81. The company’s stock had a trading volume of 160,205 shares, compared to its average volume of 2,652,275. The company has a quick ratio of 1.00, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. Danaher Corporation has a one year low of $76.27 and a one year high of $94.24. The stock has a market capitalization of $65,219.94, a price-to-earnings ratio of 24.10, a PEG ratio of 2.23 and a beta of 1.02.

Danaher Corporation (NYSE:DHR) last released its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, beating the consensus estimate of $0.95 by $0.05. Danaher Corporation had a return on equity of 11.29% and a net margin of 13.36%. The company had revenue of $4.53 billion for the quarter, compared to analyst estimates of $4.47 billion. During the same period last year, the company posted $0.87 earnings per share. The firm’s revenue was up 9.6% compared to the same quarter last year. research analysts predict that Danaher Corporation will post 3.99 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 27th. Shareholders of record on Friday, September 29th were given a $0.14 dividend. This represents a $0.56 annualized dividend and a yield of 0.60%. The ex-dividend date was Thursday, September 28th. Danaher Corporation’s dividend payout ratio (DPR) is presently 16.52%.

In other Danaher Corporation news, SVP Daniel Raskas sold 37,870 shares of the firm’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $93.33, for a total value of $3,534,407.10. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider William King sold 43,688 shares of the firm’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $82.86, for a total value of $3,619,987.68. Following the completion of the transaction, the insider now directly owns 45,748 shares in the company, valued at $3,790,679.28. The disclosure for this sale can be found here. Insiders sold 317,498 shares of company stock worth $28,838,801 over the last three months. 12.20% of the stock is currently owned by corporate insiders.

Several brokerages recently weighed in on DHR. Robert W. Baird increased their target price on Danaher Corporation from $87.00 to $97.00 and gave the stock an “outperform” rating in a research report on Friday, October 20th. Credit Suisse Group increased their target price on Danaher Corporation from $93.00 to $96.00 and gave the stock an “outperform” rating in a research report on Friday, October 20th. Morgan Stanley increased their target price on Danaher Corporation from $95.00 to $98.00 and gave the stock an “overweight” rating in a research report on Friday, October 20th. Zacks Investment Research raised Danaher Corporation from a “hold” rating to a “buy” rating and set a $97.00 target price on the stock in a research report on Thursday, October 5th. Finally, J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $95.00 target price on shares of Danaher Corporation in a research report on Friday, September 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $93.31.

TRADEMARK VIOLATION NOTICE: This report was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.dailypolitical.com/2017/11/24/yhb-investment-advisors-inc-has-8-05-million-stake-in-danaher-corporation-dhr.html.

Danaher Corporation Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR).

Institutional Ownership by Quarter for Danaher Corporation (NYSE:DHR)

Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.